Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
07 Novembro 2024 - 6:30PM
Business Wire
IPS test validation study data will be unveiled
at the 2024 SITC Annual Meeting
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the
adoption of AI to advance precision medicine and patient care,
today announced the clinical launch of its Immune Profile Score
(IPS) algorithmic test. IPS, which is now available for clinicians
to order, is a multimodal biomarker that can be used as a
prognostic indicator for adult patients with stage IV and
metastatic pan-solid tumors who are already considered candidates
for immune checkpoint inhibitor (ICI)-based therapy. Tempus is
presenting the results of its validation study at the 2024 Society
for Immunotherapy of Cancer (SITC) Annual Meeting, which
demonstrated that IPS-High patients in the study were more likely
to have an overall survival benefit while receiving ICI-based
therapy than IPS-Low patients in the study (HR 0.45).
Tempus validated IPS in a retrospective study involving 1,600
metastatic and/or stage IV adult patients with 19 different solid
tumor types from the company’s real-world de-identified database.
The study also demonstrated that IPS has prognostic utility that is
independent of tumor mutational burden (TMB), PD-L1
immunohistochemistry (IHC), and microsatellite instability (MSI)
status in the study cohort. Tempus’ IPS is a laboratory developed
test that assesses a combination of immunotherapy-related
biomarkers from DNA and RNA test results to calculate a score from
0-100 and a classification of either IPS-Low or IPS-High. IPS is a
unique biomarker that, in addition to being used in clinical
practice, is available for life science research to help facilitate
the expansion of indications for ICI therapies in order to enhance
patient selection and treatment outcomes.
"This is Tempus’ first time leveraging a multimodal algorithm in
the immunotherapy space, and we look forward to providing
clinicians the ability to use our IPS test to garner data-driven
insights that can inform important treatment decisions," said Ezra
Cohen, MD, Chief Medical Officer of Oncology at Tempus. "We are
excited to introduce this innovative test to clinicians, empowering
them with the ability to make more informed choices for their
patients while simultaneously moving the field forward in
meaningful ways."
"This study demonstrates that IPS scoring is beneficial in that
it can identify patients, independent of standard biomarkers, who
may have better overall survival with ICI therapy," said Sandip
Patel, MD, Professor at UC San Diego Health. "IPS scoring can
inform tumor-intrinsic sensitivity to immune checkpoint blockade
beyond PD-L1 IHC and TMB, and help manage patients on immunotherapy
utilizing data already collected as part of DNA and RNA
sequencing."
The IPS test is now available as an add-on option for clinicians
ordering Tempus’ xT (DNA) and xR (RNA) assays. For more information
on the validation study, visit tempus.com/publications.
About Tempus
Tempus is a technology company advancing precision medicine
through the practical application of artificial intelligence in
healthcare. With one of the world’s largest libraries of multimodal
data, and an operating system to make that data accessible and
useful, Tempus provides AI-enabled precision medicine solutions to
physicians to deliver personalized patient care and in parallel
facilitates discovery, development and delivery of optimal
therapeutics. The goal is for each patient to benefit from the
treatment of others who came before by providing physicians with
tools that learn as the company gathers more data. For more
information, visit tempus.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended (the “Securities Act”), and Section 21E of the Securities
Exchange Act of 1934, as amended, about Tempus and Tempus’ industry
that involve substantial risks and uncertainties. All statements
other than statements of historical facts contained in this press
release are forward-looking statements, including, but not limited
to, statements regarding the potential impact and uses of IPS and
other tests. In some cases, you can identify forward-looking
statements because they contain words such as “anticipate,”
“believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “going to,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” or “would” or the
negative of these words or other similar terms or expressions.
Tempus cautions you that the foregoing may not include all of the
forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions
of future events. Tempus has based the forward-looking statements
contained in this press release primarily on its current
expectations and projections about future events and trends that it
believes may affect Tempus’ business, financial condition, results
of operations and prospects. These forward-looking statements are
subject to risks and uncertainties related to: Tempus’ financial
performance; the ability to attract and retain customers and
partners; managing Tempus’ growth and future expenses; competition
and new market entrants; compliance with new laws, regulations and
executive actions, including any evolving regulations in the
artificial intelligence space; the ability to maintain, protect and
enhance Tempus’ intellectual property; the ability to attract and
retain qualified team members and key personnel; the ability to
repay or refinance outstanding debt, or to access additional
financing; future acquisitions, divestitures or investments; the
potential adverse impact of climate change, natural disasters,
health epidemics, macroeconomic conditions, and war or other armed
conflict, as well as risks, uncertainties, and other factors
described in the section titled “Risk Factors” in Tempus’ Quarterly
Report on Form 10-Q for the quarter ended September 30, 2024 filed
with the Securities and Exchange Commission (“SEC”) as well as in
other filings Tempus may make with the SEC in the future. In
addition, any forward-looking statements contained in this press
release are based on assumptions that Tempus believes to be
reasonable as of this date. Tempus undertakes no obligation to
update any forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241107783271/en/
Tempus Communications Erin Carron media@tempus.com
Tempus AI (NASDAQ:TEM)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Tempus AI (NASDAQ:TEM)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024